Equities

Zhejiang Hisun Pharmaceutical Co Ltd

600267:SHH

Zhejiang Hisun Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)7.07
  • Today's Change-0.07 / -0.98%
  • Shares traded4.82m
  • 1 Year change-35.08%
  • Beta1.0800
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,4131,3991,180
Total Receivables, Net2,5572,8022,788
Total Inventory1,9571,9142,023
Prepaid expenses258255255
Other current assets, total17439119
Total current assets6,3596,4096,364
Property, plant & equipment, net8,2529,1019,754
Goodwill, net----1.42
Intangibles, net1,2411,5211,593
Long term investments1,5141,5891,468
Note receivable - long term------
Other long term assets--5215
Total assets17,61318,78519,374
LIABILITIES
Accounts payable8681,0311,008
Accrued expenses453400558
Notes payable/short-term debt2,6032,8994,803
Current portion long-term debt/capital leases1,059640569
Other current liabilities, total1,6012,1641,847
Total current liabilities6,5847,1338,785
Total long term debt2,3983,0892,796
Total debt6,0596,6288,167
Deferred income tax232521
Minority interest24725142
Other liabilities, total260207427
Total liabilities9,51110,70512,071
SHAREHOLDERS EQUITY
Common stock1,2081,1981,196
Additional paid-in capital4,3464,1633,511
Retained earnings (accumulated deficit)2,5362,8292,500
Treasury stock - common(341)(550)(338)
Unrealized gain (loss)2.72----
Other equity, total350439434
Total equity8,1028,0797,303
Total liabilities & shareholders' equity17,61318,78519,374
Total common shares outstanding1,1721,1431,161
Treasury shares - common primary issue365635
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.